Literature DB >> 17664833

Prevalence of Aspergillosis in chronic lung diseases.

M Shahid1, A Malik, R Bhargava.   

Abstract

Eighty eight patients of chronic lung diseases (CLD) attending TB and Chest department of J.N. Medical college Hospital were studied to find out the prevalence of Aspergillus in Broncho-alveolar Lavage (BAL) and anti- aspergillus antibodies in their sera. Direct microscopy and fungal culture of BAL was done. Antibodies were studied by immunodiffusion (ID) and Enzyme linked immunosorbent assay (ELISA). Dot blot assay for anti-aspergillus antibodies was also performed in sera of patients which were either positive by ID or by ELISA. Aspergillus was isolated in culture from 13(14.7%) cases of CLD, while, 30.6% cases showed anti-aspergillus antibodies by serological methods. Aspergillus fumigatus was the predominant species isolated. 17(19.3%) cases of CLD showed antibody against Aspergillus by ID, 22(25%) by ELISA, while 19 of 27 seropositive cases also showed positive results by Dot Blot assay. In cases of bronchogenic carcinoma and pulmonary tuberculosis, anti-aspergillus antibodies were detected equally by ID and ELISA in 21.42% and 21.05% cases respectively. In bronchial asthma, the antibodies could be detected in 60% cases by ELISA, while, in only 10% cases by ID. ELISA was found more sensitive than ID for detection of anti-aspergillus antibodies. The sensitivity of Dot Blot lies some what between ID and ELISA. It is concluded that prevalence of Aspergillosis is quite high in chronic lung diseases, culture and serological test should be performed in conjunction and more than one type of serological tests should be performed to establish the diagnosis.

Entities:  

Year:  2001        PMID: 17664833

Source DB:  PubMed          Journal:  Indian J Med Microbiol        ISSN: 0255-0857            Impact factor:   0.985


  10 in total

1.  Prevalence of chronic pulmonary aspergillosis in patients with tuberculosis from Iran.

Authors:  M T Hedayati; Y Azimi; A Droudinia; B Mousavi; A Khalilian; N Hedayati; D W Denning
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-05-24       Impact factor: 3.267

2.  Fungal colonization in patients with chronic respiratory diseases from Himalayan region of India.

Authors:  Debasis Biswas; Sonal Agarwal; Girish Sindhwani; Jagdish Rawat
Journal:  Ann Clin Microbiol Antimicrob       Date:  2010-09-20       Impact factor: 3.944

3.  Clinico-microbiological profile of chronic pulmonary aspergillosis from a tertiary care centre in southern India.

Authors:  Kiran Chawla; Kranthi Kosaraju; Sridevi Rayasam; Chiranjay Mukhopadhyay
Journal:  J Clin Diagn Res       Date:  2013-12-15

4.  Pulmonary aspergillosis and aflatoxins in chronic lung diseases.

Authors:  Sana Ali; Abida Malik; Mohd Shahid; Rakesh Bhargava
Journal:  Mycopathologia       Date:  2013-08-15       Impact factor: 2.574

5.  Estimation of the burden of chronic and allergic pulmonary aspergillosis in India.

Authors:  Ritesh Agarwal; David W Denning; Arunaloke Chakrabarti
Journal:  PLoS One       Date:  2014-12-05       Impact factor: 3.240

6.  Aspergillus colonization in patients with chronic obstructive pulmonary disease.

Authors:  M Shahi; S A Ayatollahi Mousavi; M Nabili; M Aliyali; S Khodavaisy; H Badali
Journal:  Curr Med Mycol       Date:  2015-09

Review 7.  Recent Advances in Diagnosing Chronic Pulmonary Aspergillosis.

Authors:  Takahiro Takazono; Koichi Izumikawa
Journal:  Front Microbiol       Date:  2018-08-17       Impact factor: 5.640

8.  Surgical treatment of pulmonary aspergillosis: A single center experience.

Authors:  Biswajeet Mohapatra; Poornima Sivakumar; Subhankar Bhattacharya; Santanu Dutta
Journal:  Lung India       Date:  2016 Jan-Feb

9.  Underlying Conditions and Clinical Spectrum of Chronic Pulmonary Aspergillosis (CPA): An Experience from a Tertiary Care Hospital in Karachi, Pakistan.

Authors:  Nousheen Iqbal; Muhammad Irfan; Ammar Mushtaq; Kauser Jabeen
Journal:  J Fungi (Basel)       Date:  2020-03-26

10.  Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation.

Authors:  Iain D Page; Rosemary Byanyima; Sharath Hosmane; Nathan Onyachi; Cyprian Opira; Malcolm Richardson; Richard Sawyer; Anna Sharman; David W Denning
Journal:  Eur Respir J       Date:  2019-03-18       Impact factor: 16.671

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.